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Abstract
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Rationale—Low circulating progenitor cell (PC) numbers and activity may reflect impaired
intrinsic regenerative/reparative potential, but it remains uncertain whether this translates into a
worse prognosis.
Objectives—To investigate whether low numbers of PCs associate with a greater risk of
mortality in a population at high cardiovascular risk.
Methods & Results—Patients undergoing coronary angiography were recruited into two
cohorts (1, n=502 and 2, n=403) over separate time periods. PCs were enumerated by flow
cytometry as CD45med+ blood mononuclear cells expressing CD34, with additional quantification
of subsets co-expressing CD133, VEGFR2 and CXCR4. Coefficient of variation for CD34 cells
was 2.9% and 4.8%, 21.6% and 6.5% for the respective subsets. Each cohort was followed for a
mean of 2.7 and 1.2 years, respectively, for the primary endpoint of all-cause death.
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There was an inverse association between CD34+ and CD34+/CD133+ cell counts and risk of
death in Cohort 1 (β=−0.92, p=0.043 and β=−1.64, p=0.019, respectively) that was confirmed in
Cohort 2 (β=−1.25, p=0.020 and β=−1.81, p=0.015, respectively). Covariate adjusted HRs in the
pooled cohort (n=905) were 3.54 (1.67-7.50) and 2.46 (1.18-5.13), respectively. CD34+/CD133+
cell counts improved risk prediction metrics beyond standard risk factors.

Address correspondence to: Dr. Arshed A. Quyyumi, Emory Clinical Cardiovascular Research Institute, Emory University School
of Medicine, 1462 Clifton Road NE, Suite 507, Atlanta, GA, 30322, USA, Tel: 404 727 3655, Fax: 404 727 8785,
aquyyum@emory.edu.
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Conclusion—Reduced circulating PC counts, identified primarily as CD34+ mononuclear cells
or its subset expressing CD133 are associated with risk of death in individuals with coronary
artery disease, suggesting that impaired endogenous regenerative capacity is associated with
increased mortality. These findings have implications for biological understanding, risk prediction
and cell selection for cell based therapies.
Keywords
Progenitor cells; CD34; flow cytometry; outcomes research; coronary artery disease; risk;
prognosis; biomarker
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Although cardiovascular risk factor-mediated injury to the vascular endothelium is well
described, little was known about mechanisms underlying regeneration until the pivotal role
of progenitor cells (PCs) in vascular repair was discovered.1-3 Circulating PCs are
mononuclear, originate primarily but not exclusively from the bone marrow, have the
potential to differentiate into several lineages and contribute to vascular repair and
regeneration.1, 2, 4, 5 CD34+ mononuclear cells from human bone marrow include distinct
lineages of both hematopoietic (CD34+/CD45med) and non-hematopoietic (mesenchymal)
progenitors.6 CD34+ cells have greater myocardial reparative potential than unselected
populations.7 CD133 is a 5-transmembrane antigen marker of primitive stem cells that is lost
during maturation, and cells expressing both markers (CD34+/CD133+) may be further
enriched for a vascular PC phenotype.8, 9 While additional expression of vascular
endothelial growth factor receptor-2 (VEGFR2) has been proposed to identify more
differentiated PCs, these sub-populations remain difficult to reproducibly quantify compared
to other more abundant CD34+ populations. Finally, co-expression of CXCR4, which
promotes homing of PCs to stromal-derived factor-enriched hypoxic environments for
enhancing repair, may also further characterize PCs with capacity for vascular repair.10

Author Manuscript

Lower counts and activity of PCs in blood are associated with cardiovascular risk factors
and vascular dysfunction, with experimental studies suggesting that diminished PC counts
reflect impaired regenerative potential.11-15 Early studies have reported an increased risk of
adverse cardiovascular events in subjects with low numbers of circulating PCs. However,
the majority of associations were driven by procedural endpoints with PCs characterized
variably as CD34+, CD133+ or CD34+/VEGFR2 dual positive cells.16-18 Whether low
circulating PC counts increase mortality in subjects at high cardiovascular risk remains
unclear. We sought to comprehensively examine the prognostic impact of CD34+ enriched
PCs in subjects with coronary artery disease (CAD) with the hypothesis that low circulating
PC counts, reflecting reduced cardiovascular regenerative capacity, will be associated with
greater mortality. As secondary endpoints we also studied the relationship between PCs and
cardiovascular death and the combined outcome of death and MI.
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METHODS
Study population
Study participants aged 20-90 years were recruited as part of the Emory Cardiovascular
Biobank, an ongoing prospective cohort of patients enrolled prior to undergoing coronary
angiography for investigation or management of CAD across three Emory Healthcare sites
with collection of data on demographic characteristics, medical history, medication use,
behavioral habits and risk factor prevalence, details of which have been published
previously.19

Author Manuscript

Two sub-cohorts were collected under the same protocol, with identical sampling strategies
and collection methods but separated in time and by a change in cell quantification
methodology (see below). Cohort 1 (n=502) was enrolled between March 2006 and
September 2008, while Cohort 2 (n=403) was collected between October 2008 and February
2011.
Recruited patients were stable at the time of enrollment and undergoing an elective
procedure, although stable patients with non-ST elevation myocardial infarction, defined
using international criteria were also included and classified as “Acute MI”.20 Obstructive
CAD was defined as >50% luminal narrowing in a major epicardial vessel and a Gensini
score calculated to quantify the burden of CAD. Patients were excluded if they had a history
of heart transplantation, immunosuppressant use, malignancy, or significant infections. The
study complies with the declaration of Helsinki and was approved by the Institutional
Review Board at Emory University with all subjects providing written informed consent.
Follow-up and endpoints

Author Manuscript

Follow-up was conducted for determination of the primary endpoint of all cause death, and
the secondary endpoints of cardiovascular death and the composite of all-cause death or MI.
This was performed by personnel blinded to PC data through telephone interview, chart
review and linkage with the Social Security Death Index and State records. Cause of death
was adjudicated by two cardiologists with a third arbitrator in case of disagreement, who
were all blinded to PC data. Cardiovascular death was defined as death attributable to an
ischemic cardiovascular cause (fatal MI, stroke, peripheral arterial disease) or sudden death
due to an unknown but presumed cardiovascular cause in high risk patients. Medical records
were accessed or requested to validate all self-reported events including MI, which was
again defined using standard criteria.20
Flow cytometry
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Arterial blood was collected via a femoral sheath in EDTA tubes prior to cardiac
catheterization after an overnight fast. Blood samples were prepared within 4 hours and
incubated with fluorochrome-labeled monoclonal anti-human mouse antibodies to identify
surface markers expressed on mononuclear cells before quantification using flow cytometry.
Further details are given in Supplementary Methods. Of note, preliminary descriptive
analysis of cohort 1 revealed very low counts of infrequent cell types. Thus for Cohort 2,
enumeration of PCs was refined by adding a fixed number of counting beads to 300uL
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whole blood and a lyse-no-wash methodology that reduced cell loss. This improved
quantification and cell counts were subsequently noted to be higher for each subset
compared to Cohort 1. Putative circulating PCs were identified in both cohorts through
expression of the CD34 surface marker on mononuclear cells that were enumerated as
CD45med+ cells with and without co-expression of CD133 (CD34+/CD133+) and VEGFR2
(CD34+/VEGFR2 and CD34+/CD133+/VEGFR2+). In Cohort 2, co-expression of an
additional marker, CXCR4 was also quantified (as CD34+/CXCR4+ and CD34+/CD133+/
CXCR4+). All cell populations were reported as cell counts/μl.

Author Manuscript

Statistical analysis—Continuous variables are presented as means (SD) or as median
(IQR) and categorical variables as proportions (%). Cell counts were non-normally
distributed and were transformed (natural log (cell count+1)) prior to parametric analyses.
Cell populations were additionally categorized by tertiles, to derive effect estimates and to
permit pooled analysis of both cohorts. Finally to assess the potential of cell counts for use
as a biomarker we derived an optimized cut off in Cohort 1 and applied this threshold (as a
percentile equivalent of the absolute value) in Cohort 2 for validation. The cut point was
identified using receiver operating characteristic (ROC) analyses and Youden's index
(Sensitivity – (1-Specificity)) (Supplementary Figure I).

Author Manuscript

Survival analysis was performed using Cox proportional-hazards regression in models
adjusted for age and gender. In the pooled cohort, further adjustment was made for body
mass index (BMI), diabetes, hypertension, low density lipoprotein (LDL), current smoking,
statin use, glomerular filtration rate (GFR), acute MI at enrollment, left ventricular ejection
fraction (LVEF) and CAD burden (Gensini Score) all at baseline. Missing covariate data for
the fully adjusted model (range 0-3%) was imputed and sensitivity analysis with un-imputed
data found results to be similar. The proportional hazards assumption for Cox models was
evaluated by plots of Schoenfeld residuals and formal testing (a chi-square test calculated as
the sum of Schoenfeld residuals), with no significant violations of the assumption found.
The incremental value of PC counts to risk prediction was tested before and after their
addition (using high v low categorization described above) to a clinical model with
traditional risk predictors. The C-statistic (AUC), category free net reclassification
improvement (NRI) and integrated discrimination improvement (IDI) were calculated as
indices of risk discrimination.21 P values of <0.05 from two-sided tests were considered to
indicate statistical significance. All statistical analyses were performed using SAS (Cary,
NC) and SPSS 20.0 (Chicago, IL).

RESULTS
Author Manuscript

Baseline patient characteristics of the 502 subjects in Cohort 1 and 403 subjects in Cohort 2
are shown in Table 1. The mean age and gender distribution was similar across cohorts (62.5
and 62.9 years; males 64.1% and 65.5%). Overall, patient characteristics were reflective of
typical populations recruited at coronary angiography, with over two thirds reporting
hypertension and hyperlipidemia and a third with diabetes.
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In 20 samples from the Cohort 2 that were repeatedly analyzed on two occasions by the
same technician, the coefficients of variation of the cell types were: CD34+ 2.9%; CD34+/
CD133+ 4.8%; CD34+/CXCR4+ 6.5% and CD34+/CD133+/CXCR4+ 7.5%. However,
CD34+/VEGF2R cells and CD34+/CD133+/VEGF2R cells showed poorer reproducibility at
21.6% and 35.9%. PC counts were generally higher in Cohort 2 due to the refined
enumeration methods described above. CD34+ and its subset of CD34+/133+ were highly
correlated with each other in each cohort (Spearman rho = 0.92 and 0.87, for Cohorts 1 & 2
respectively) with more modest correlations between other cell types (Supplementary Table
I).
Relationship between PCs and demographic and clinical features
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In Cohort 1, lower CD34+ and CD34+/CD133+ cell counts were univariately associated
with higher age, male gender, impaired renal function, obstructive CAD and history of prior
MI. Lower CD34+/CD133+ cells were also associated with CAD burden (Gensini Score)
and history of PAD. The associations between both cell types with age, gender and renal
function were replicated in Cohort 2 in which there were further modest correlations
between lower cell counts and lower BMI, higher HDL (inverse) and current smoking
(Supplementary Tables II & III).
We did not observe consistent associations between any of the studied cell types and other
cardiovascular risk factors such as diabetes, hypertension or features such as statin use, LV
function, history of stroke or presence or absence of an acute MI at enrollment.
Relationship between PC populations and adverse outcomes
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During a combined 1800 person-years of follow up, there were 71 deaths.
CD34+ and CD34+/CD133+ cells—In cohort 1 (n=502), Cox Regression analysis
adjusted for age and gender revealed that both CD34+ and CD34+/CD133+ counts were
inversely associated with the primary end-point of all cause death (p=0.043 and p=0.019,
respectively) (Table 2). When categorized into tertiles, those subjects in the lowest tertile of
CD34+ cell counts had a greater than 4.6-fold risk of death compared to those in the highest
tertile group (HR 4.63 (95% CI, 1.59-13.5)). There was a similar 3-fold increase in the ageand gender-adjusted risk of death for those in the lowest tertile of CD34+/CD133+ cell
counts (HR 3.09 (95% CI, 1.15-8.33)). For both cell types there was a graded increase in
effect size per tertile (Table 2 & Figure 1).

Author Manuscript

In Cohort 2 (n=403), the age- and gender-adjusted association between CD34+ and CD34+/
CD133+ counts and the primary endpoint was replicated (p=0.019 and p=0.015,
respectively)(Table 3). Similarly, those in the lowest tertile of CD34+ cell counts (HR 3.43
(95% CI, 1.23-9.59)) and those in the lowest tertile of CD34+/CD133+ cells (HR 2.93 (95%
CI, 1.05-8.21)) had increased risk of death compared to those in the highest tertile of each
cell type (Table 3).
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In the pooled cohort of 905 subjects, those in the lowest tertile of CD34+ and CD34+/
CD133+ cells had age- and gender-adjusted HRs of 3.87 (95% CI, 1.86-8.06) and 3.06 (95%
CI, 1.50-6.24) for the primary endpoint of all-cause death when compared to subjects in the
highest tertile categories (Table 4). After fully adjusting for likely confounders (age, gender,
BMI, diabetes, hypertension, LDL, Smoking, GFR, statin use, Gensini score, LVEF, AMI),
these associations persisted with HRs of 3.54 (95% CI, 1.67-7.50) and 2.46 (95% CI,
1.18-5.13) for CD34+ and CD34+/CD133+ cells, respectively (Table 4).
Significant associations between CD34+ and CD34+/CD133 cell types were also observed
for the secondary endpoints of cardiovascular death and the composite of death/MI
combined (Tables 2-4).

Author Manuscript

CD34+/CD133− (negative) cells—Among the CD34+ population, cells that did not
express CD133 (CD34+/CD133−) did not show association with risk of all cause death in
Cohort 1 (p=0.132) or in Cohort 2 (p=0.07).
VEGFR2+ cells—Co-expression of VEGFR2 on CD34+ or CD34+/CD133+ cells was not
associated with mortality in either cohort (data not shown).
CXCR4+ cells—CXCR4 co-expression enumerated in Cohort 2 (n=403) demonstrated
marginal association between lower counts of CD34+/CXCR4+ cells and risk of all-cause
death in age- and gender-adjusted models (p=0.07). Those in the lowest tertile of CD34+/
CXCR4+ cell counts had a HR of 2.77 (95% CI, 1.04-7.39) for risk of death compared to
those in the top tertile (Supplementary Table IV). Cells co-expressing both CXCR4 and
CD133 (CD34+/CD133+/CXCR4+) demonstrated similar borderline association with risk of
death (Supplementary Table IV).
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Finally, we also examined the predictive value of all CD133+ and all CXCR4 expressing
cell counts within the mononuclear cell populations (unselected for CD34) and found that
they were not significantly associated with mortality (Supplementary Table V).
Sensitivity analyses
There were no interactions when sensitivity analyses were performed for CD34+ cell counts
with respect to age, gender and risk factors in both cohorts separately (Supplementary Table
VI). Although there was an interaction for obstructive CAD in Cohort 2 and LV function in
Cohort 1, this was not consistent interactions across both cohorts. Specifically, the effect of
CD34+ cells on mortality was not modified by acute MI at enrollment or presence of other
ischemic conditions (PAD, Stroke).

Author Manuscript

Risk discrimination testing
To determine the potential of PCs as biomarkers in exploratory analysis, we identified
thresholds of 0.737 counts/μl for CD34+ cells (37th centile) and 0.504 counts/μl for CD34+/
CD133+ cells (46th centile) using Youden's index for the primary endpoint in Cohort 1 and
sought to validate these in Cohort 2 (Supplementary Figure I). Counts of CD34+ and
CD34+/CD133+ cells below the relevant thresholds were associated with increased risk of
death after adjustment for age and gender (HR 2.15 (95% CI, 1.16-3.97) and HR 3.16 (95%
Circ Res. Author manuscript; available in PMC 2016 January 16.
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CI, 1.49-6.72)), respectively in Cohort 1. These findings were fully replicated in Cohort 2
with similar results with risk of death for “low” values of each cell type (HR 2.79 (95% CI,
1.31-5.96) and HR 3.27 (95% CI, 1.37-7.83)), respectively. In the pooled cohort, a low
CD34+ count and CD34+/CD133+ count were associated with a HR of 2.24 (95% CI,
1.37-3.66) and 2.83 (95% CI, 1.57-5.12), respectively, compared to high counts, after full
adjustment for the aforementioned covariates.
Finally, in the pooled cohort, we tested the incremental value of this threshold driven PC
count. The C statistic for prediction of death, when compared to a model with clinical risk
predictors, increased marginally with the addition of CD34+ cells (Δ 0.020, p=0.07) but
more significantly with the addition of CD34+/CD133+ cells (Δ 0.028, p=0.04). The
category free NRI and IDI metrics were also significant for a model including CD34+/
CD133+ cell counts compared to clinical model alone (Table 4).

Author Manuscript

DISCUSSION
In the largest prospective study of patients with CAD phenotyped for circulating PCs to
date, we demonstrate that low numbers of blood hematopoietic PCs, characterized as CD34+
mononuclear cells are predictive of incident risk of all-cause death, independent of other risk
determinants. Of these, both CD34+ cells and those co-expressing CD133 appear to be the
most robustly associated with adverse events, such that in two successive cohorts totaling
over 900 subjects, the risk of death was >2.5-fold greater in those in the lowest compared to
highest tertile of these cell counts. Furthermore, the CD34+/CD133+ cell count added
incremental predictive value to clinical risk factors using risk discrimination indices.
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The stromal derived factor-1 receptor CXCR4 is required for homing of PCs and identifies
cells with greater capacity for migration and neo-vascularization.10 However, the association
between CD34+ cells co-expressing CXCR4 and death was modest and less robust than the
CD34+ or the CD34+/CD133+ populations. This may be partly because CXCR4 was
enumerated in only one population.
In addition, and in contrast to other studies, we found no association between CD34+ cells
co-expressing VEGFR2 and outcomes in either cohort, possibly because of their very low
frequency and poor reproducibility of measurement.17, 18 In contrast quantification of total
CD34+ cells and the CD34+/CD133+ subset is more practical and reproducible.
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The mechanisms by which reduced circulating PCs are associated with death is unknown,
but based on experimental data likely represents increased risk due to impaired endogenous
regenerative and repair capacity. While CD34+ cells are heterogeneous, they are enriched
for cells expressing endothelial marker genes and form endothelial structures in vitro and in
vivo.1, 22 Moreover, pro-angiogenic activity is lacking in selected CD34− cells.7 In our
study, CD34+ cells of interest in the blood were predominantly (>95%) CD45med+, and thus
largely represent cells of the hematopoietic lineage. Of note, CD34+ cells expressing the
CD133+ epitope, which are believed to be early or immature PCs, more precisely reflect risk
than CD34+ cells without the CD133 epitope, that had no association with risk. While the
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additional expression of VEGFR2 receptor on CD34+/CD133+ cells is often considered to
define a subset enriched for endothelial PCs, this remains a subject of controversy.8, 23-26
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Three smaller studies have previously reported association between various PC subsets and
cardiovascular outcomes.16-18 In 120 subjects with and without CAD an association between
CD34+/VEGFR2+ cell counts and adverse events was found with just 11 events.17 This was
confirmed in a larger study with largely revascularization events.18 Finally, in subjects
enriched for metabolic syndrome, cardiovascular events were more frequent in those with
low CD34+ cell counts,16 findings that were confirmed in a meta-analysis.27 These studies
were generally smaller, more heterogeneous, did not enumerate CD45med+ subsets, assessed
cardiovascular events that were predominantly revascularization or hospitalizations, and did
not perform discriminatory analyses. In contrast, our study represents the largest cohort
phenotyped for PCs using flow cytometry (at the time of collection) and prospectively
followed for mortality. Additionally, our 2 cohort strategy, separated in time and
methodology lends further confidence to our findings. Importantly, and in contrast to
previous studies, our findings were most robust for the CD34+ and CD34+/CD133+ cell
subsets and not for cells co-expressing VEGFR2.
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We and others have previously demonstrated that lower circulating PC counts characterized
by flow cytometry or cell culture are associated with endothelial dysfunction and established
risk factors.12, 13 In cross sectional analyses, we confirmed associations between lower PC
counts and advanced age and impaired renal function.12, 15, 28 We also found that higher
counts were associated with male gender, higher BMI and lower HDL. Although acute and
chronic ischemia may influence PC mobilization, we did not observe any associations or
interactions with acute myocardial infarction at enrolment or prior conditions such as PAD
or stroke.30, 31
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Strengths of our study include (1) a large prospective single center study design to limit
heterogeneity, (2) use of commonly used high throughput technology (flow cytometry) for
quantification of PCs by the same technical team, (3) a 2 cohort analysis strategy, and (4)
exploration of a selection of CD34+ cell sub-populations. The change in methodology
between the two cohorts may be considered a limitation, but is also a strength in that the
associations were fully replicated under different measurement settings. Limitations of our
study are that we only examined a high risk population undergoing angiography, and
therefore our conclusions may not be applicable to the general population. Absence of
longitudinal measurements or assessments of cell functionality also limit the conclusions
that could be drawn about CD34+ cells and their long term impact on health. Finally, the
observational nature of this analysis does not imply causation and thus further interventional
studies directly influencing PC levels are required. Studies demonstrating improvements in
intermediate phenotypes, such as endothelial function with PC mobilization suggest that this
could be feasible.32
There are important implications of our findings: (1) CD34+ cells that are enriched for bone
marrow-derived hematopoietic and endothelial progenitors may represent an index of global
regenerative potential, a view supported by findings of worse prognosis in patients with
lower numbers of PCs in the settings of acute lung injury, renal failure, and stroke;33-35 (2)
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Quantification of these cell subtypes could be used to identify those individuals with CHD at
greatest risk of subsequent events as part of an enhanced risk prediction model, including
demographic, clinical features and other novel biomarkers; (3) In addition, CD34+ cells
could also represent a potentially modifiable risk factor and thus a new target for therapeutic
interventions, a possibility currently under active study;36 (4) Either CD34+ or CD34+/
CD133+ cell counts could be used equally effectively as a ‘biomarker’ of regenerative
capacity; and (5) These findings could influence cell based therapy by supporting targeted
selection and harvesting of these particular PC subsets.
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In conclusion, we have demonstrated that fewer circulating PCs, identified primarily as
CD34+ mononuclear cells are associated with risk of death in individuals at high
cardiovascular risk. Both CD34+ and CD34+/CD133+ subset are predictive of future
adverse events, and potentially represent endogenous regenerative capacity. These findings
have implications for biological understanding, risk prediction and cell selection for cell
based therapies.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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PCs

Progenitor Cells

HR

Hazard ratio

FACS

Fluorescence Activated Cell Sorting

VEGFR2

Vascular Endothelial Growth Factor Receptor 2

CXCR4

Chemokine (C-X-C motif) Receptor 4

MI

Myocardial Infarction

CAD

Coronary Artery Disease

ROC

Receiver Operating Characteristic

NRI

Net Reclassification Index

IDI

Integrated Discrimination Improvement
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Novelty and Significance
What Is Known?
•

Circulating progenitor cells play a role in vascular repair and regeneration.

•

Mononuclear cells (MNCs) expressing CD34 and CD133 epitopes constitute a
population of cells enriched for hematopoietic and/or endothelial progenitor
cells (PCs), and their circulating levels are modulated by risk factors.

What New Information Does This Article Contribute?

Author Manuscript

•

The numbers of circulating MNCs expressing CD34 alone or in combination
with CD133 are independent predictors of death in patients with coronary heart
disease (CHD), such that patients in the lowest tertile had 3-fold greater
mortality compared with those in the highest tertile.

•

Circulating PC counts reflect endogenous reparative capacity and are
independent predictors of survival in CHD.

Author Manuscript

Although the injurious effects of cardiovascular risk factors in the pathogenesis of
atherosclerosis are known, the role of innate repair and regeneration in mitigating this
damage remains to be studied. Since circulating PCs represent endogenous regenerative
potential, we investigated whether survival in patients with CHD is associated with PC
levels. In a large cohort of patients with CHD, we found that the circulating numbers of
MNCs expressing CD34 alone or in combination with CD133, predicted incident death,
cardiovascular death, and the composite endpoint of death and myocardial infarction.
After adjusting for relevant risk factors, there was an almost 3-fold increase in mortality
in those with PC levels in the lowest tertile compared to those in the highest tertile. The
CD34+/CD133+ cell count added incremental predictive value to clinical risk factors,
indicating its additive value as a biomarker for risk prediction in patients with CHD.
Thus, circulating levels of CD34+ and CD34+/CD133+ PCs, are novel predictors of
survival in CHD, and may be useful biomarkers in risk prediction and potentially targets
for therapeutic interventions.
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Figure 1.
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Survival curves adjusted for age and gender, for the primary endpoint of death by tertiles of
CD34+ (upper panel) and CD34+/133+ (lower panel) cell counts. Results are show
separately for Cohorts 1 and 2 and the combined “pooled” cohort. Colored lines represent
tertiles of PC counts (Blue=top tertile; Green=middle tertile; Red=bottom tertile). P values
for effect estimate in Cox regression model.
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Baseline Patient Characteristics
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Cohort 1

Cohort 2

N

502

403

Age, years

62.5 (11.6)

62.9 (13.2)

0.60

Male, %

64.3

65.6

0.68

Caucasian, %

71.4

69.5

0.52

Body Mass Index (BMI), kg/m2

30.3 (6.7)

29.3 (6.78)

0.03

Hypertension, %

74.2

88.6

<0.001

Systolic BP, mmHg

140.2 (21.8)

141.1 (23.1)

0.55

Hyperlipidemia, %

76.1

73.7

0.36

Total Cholesterol, mg/dL

170.3 (45.8)

163.6 (48.8)

0.04

Low Density Lipoprotein, mg/dL

99.3 (40.6)

95.0 (42.0)

0.12

High Density Lipoprotein, mg/dL

41.9 (13.2)

41.5 (14.2)

0.72

Diabetes Mellitus,%

31.0

33.0

0.43

Current Smoking,%

17.9

16.0

0.44

Prior Myocardial Infarction (MI), %

28.6

23.8

0.10

Prior CABG, %

20.9

19.9

0.70

Prior Heart Failure, %

20.8

23.1

0.38

Prior Peripheral Arterial Disease, %

17.6

10.0

0.001

Prior Stroke, %

8.0

15.2

0.001

Acute MI at Enrollment, %

10.8

10.7

0.98

Left Ventricular Ejection Fraction %

54.5 (11.1)

53.2 (13.0)

0.12

Renal Function (GFR), ml/min

89.4 (38.4)

84.9 (44.6)

0.08

Statin Use, %

79.0

65.0

<0.001

Obstructive CAD >50%, %

67.5

65.1

0.45

Gensini CAD Score, median (range)

10 (0-33.9)

8 (0-34.1)

0.16

PCI or CABG at Enrollment, %

45.9

38.0

0.02

CD34+

1.038 (0.63-1.65)

1.833 (1.10-2.75)

-

CD34+/CD133+

0.535 (0.30-0.93)

0.756 (0.48-1.19)

-

CD34+/VEGF2R+

0.051 (0.02-0.10)

0.189 (0.10-0.35)

-

CD34+/CXCR4+

n/a

0.974 (0.63-1.53)

-

CD34+/CD133+/CXCR4+

n/a

0.398 (0.24-0.67)

-

CD34+/VEGFR2+/CXCR4+

n/a

0.180 (0.09-0.34)

-

Follow up duration, years

2.66 (1.91)

1.18 (0.51)

-

All-cause deaths, n (%)

42 (8.4)

29 (7.2)

-

Cardiovascular deaths, n (%)

39 (7.8)

25 (6.2)

-

Death or non-fatal MI, n (%)

57 (11.3)

35 (8.7)

-

Cell Populations (Counts/uL)

P value

*

Follow up
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Secondary endpoints

Mean (SD) shown unless stated
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GFR – Glomerular Filtration Rate; CAD – Coronary Artery Disease; PCI – Percutaneous Coronary Intervention; CABG – Coronary Artery Bypass
Grafting
*

Cell Counts shown as median (IQR)
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−1.64, p=0.019

−1.55, p=0.032

−1.76, p=0.004

Death

CV Death

Death/ MI
1
2.34 (0.97-5.62), 0.059
3.69 (1.60-8.53), 0.002

T2
T1

3.37 (1.13-10.0), 0.029

T1
T3 - ref

3.07 (1.01-9.31), 0.048

T2

3.09 (1.15-8.33), 0.026

T1
1

2.51 (0.91-6.96), 0.077

T3 - ref

1

3.58 (1.64-7.83), 0.001

T1

T2

1.88 (0.79-4.44), 0.151

T2

T3 - ref

1

4.1 (1.39-12.06), 0.010

T1
T3 - ref

3.06 (0.99-9.45), 0.052

3.64 (1.89-6.98), <0.001

3.25 (1.47-7.18), 0.004

3.16 (1.49-6.72), 0.003

2.54 (1.49-4.33), 0.001

2.07 (1.10-3.91), 0.025

2.15 (1.16-3.97), 0.015

HR, (95% CI), p value

Threshold cut-off – using ROC

Cut offs equivalent to 37% for CD34+ and 46% for CD34+/CD133+ (see methods)

*

All values adjusted for age and gender. Beta values are for natural log+1 transformed cell counts

CD34+/ CD133+

−0.93, p=0.017

Death/ MI

1

4.63 (1.59-13.5), 0.005

T1

T2

3.42 (1.11-10.4), 0.031

T2

T3 - ref

1

HR, (95% CI), p value

T3 - ref

Tertiles

−0.92, p=0.043

Beta, p value

−0.86, p=0.067

Death

CD34+

Tertiles

Continuous

CV Death

Outcome

Cell Type

*
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Association between CD34+ and CD34+/CD133+ cells and outcomes for Cohort 1 (n=503)
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−1.81, 0.015

−1.51, 0.044

-−1.39, 0.028

Death

CV Death

Death/ MI
1.23 (0.48-3.17), 0.678
2.16 (0.92-5.08), 0.078

1

T2

2.52 (0.88-7.22), 0.084

T1
T3 - ref

1.68 (0.55-5.12), 0.360

T2

2.93 (1.05-8.21), 0.041

T1
1

1.69 (0.56-5.15), 0.355

T3 - ref

1

2.91 (1.19-7.11), 0.019

T1

T2

1.44 (0.55-3.78), 0.463

T2

T3 - ref

1

2.97 (1.04-8.46), 0.042

T1
T3 - ref

1.56 (0.51-4.80), 0.445

Applying cut offs derived from Cohort 1 using 37%/46% thresholds.

*

*

2.57 (1.25-5.32), 0.010

3.61 (1.53-8.55), 0.003

3.27 (1.37-7.83), 0.008

2.45 (1.24-4.85), 0.101

2.43 (1.11-5.31), 0.026

2.79 (1.31-5.96), 0.008

HR, (95% CI), p value

Threshold cut-off derived from Cohort 1

All values adjusted for age and gender. Beta values are for natural log+1 transformed cell counts

CD34+/ CD133+

−1.13, 0.018

Death/ MI

1

3.43 (1.23-9.59), 0.019

T1

T2

1.57 (0.51-4.83), 0.431

T2

T3 - ref

1

HR, (95% CI), p value

T3 - ref

Tertiles

−1.25, 0.020

Beta, p value

−1.02, 0.064

Death

CD34+

Tertiles

Continuous

CV Death

Outcome

Cell Type

Association between CD34+ and CD34+/CD133+ cells and outcomes for Cohort 2 (n=402)
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Death/ MI

CV Death

Death

Death/ MI

1
1.76 (0.93-3.31), 0.080
2.96 (1.64-5.33), <0.0001

T2
T1

2.95 (1.39-6.25), 0.005

T1
T3 - ref

2.34 (1.08-5.06), 0.032

T2

3.06 (1.50-6.24), 0.002

T1
1

2.13 (1.01-4.50), 0.046

T3 - ref

1

T2

3.25 (1.81-5.83), <0.0001

T1
T3 - ref

1.72 (0.91-3.27), 0.098

T2

3.39 (1.61-7.13), 0.001

T1
1

2.31 (1.05-5.06), 0.036

T3 - ref

1

3.87 (1.86-8.06), <0.001

T1

T2

2.47 (1.13-5.37), 0.023

T2

T3 - ref

1

HR, (95% CI), p value

T3 - ref

Tertiles

*

Tertiles

2.54 (1.38-4.67), 0.003

1.80 (0.95-3.41), 0.072

1

2.36 (1.08-5.14), 0.031

2.47 (1.13-5.41), 0.024

1

2.46 (1.18-5.13), 0.017

2.23 (1.05-4.74), 0.037

1

3.07 (1.69-5.58), <0.001

1.63 (0.85-3.14), 0.144

1

3.05 (1.42-6.53), 0.004

2.27 (1.02-5.10), 0.046

1

3.54 (1.67-7.50), 0.001

2.36 (1.07-5.25), 0.034

1

HR, (95% CI), p value

Tertiles - Fully adjusted

**

3.20 (1.98-5.18), <0.0001

3.33 (1.85-5.99), <0.0001

3.42 (1.94-6.04), <0.0001

2.47 (1.62-3.76), <0.0001

2.16 (1.32-3.53), 0.002

2.35 (1.46-3.78), <0.0001

HR, (95% CI), p value

*

Threshold cut-off

2.79 (1.70-4.60), <0.0001

2.74 (1.48-5.05), 0.001

2.83 (1.57-5.12), 0.001

2.44 (1.58-3.77), <0.0001

2.00 (1.20-3.32), 0.008

2.24 (1.37-3.66), 0.001

HR, (95% CI), p value

**

Threshold Fully adjusted

Adjusted for age, gender, bmi, diabetes, hypertension, LDL, smoking, renal function (GFR), statin use, CAD burden (Gensini score), LV function (EF), Acute MI at enrolment

**

Adjusted for age and gender only

*

CD34+/CD133+

Death

CD34+

CV Death

Outcome

Cell Type

Association between CD34+ and CD34+/CD133+ cells and outcomes for the pooled cohort (n=905)
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0.806
0.814

Model + CD34+ cells

Model + CD34+/CD133+ cells

0.042

0.069

-

P value for ΔC-statistic

0.664

0.504

-

Category Free NRI

NRI

<0.001

<0.001

-

P value

0.024

0.013

-

IDI

IDI

0.0006

0.058

-

P value

NRI = Net Reclassification Index; IDI = Integrative Discriminatory Index

Model = Includes age, gender, hypertension, diabetes, smoking, LDL, renal function (GFR), LV function (LVEF), acute MI at baseline

CD34+ and CD34+/CD133+ cells categorized as low v high levels using the derived thresholds (see methods)

0.786

C-statistic (95% CI)

C-statistic

Model

Model

0.247

0.138

-

Relative IDI

Risk prediction metrics for CD34+ and CD34+/133+ cell counts in the combined cohort for the primary outcome of death (n=905)
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